Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414609 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
NCT00414609: Completed Phase 3 study, sponsored by Novartis.
NCT00414609 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 820 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00414609, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
Study Summary
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
Primary Outcome
Change from baseline to end of study in left ventricular end systolic volume (LVESV) as measured by echocardiography. LVESV is a measurement of the volume of blood in the heart's left ventricular chamber at the end of the heart's contraction. This measurement was made by the echocardiography lab. LVESV values between 22 to 58 mL for men and 19-49 mL for women are considered normal. Baseline LVESV was a covariate.
Interventions
- DRUG placebo
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT00414609 record still lists
NCT00414609 is an interventional study that assigns participants to a tested intervention. The registered 820 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00414609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00414609 about?
NCT00414609 is a clinical study titled "Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)". The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
What is the current status of trial NCT00414609?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2006-12. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00414609?
The interventions under investigation include: placebo (DRUG), Aliskiren (DRUG).
Who is sponsoring clinical trial NCT00414609?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00414609's enrollment target sits among peer trials
820 404th of 2000 higher than 1,596 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
- NCT04910269 · 820 participants · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia